S4-E19.4 - Patient Advocates Describe the Reasoning Behind Their Testimonies

Send us Fan MailBack in March 2023, Jeff McIntyre (GLI) introduced a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. The Surfers dedicated an episode to expand on the contents, its shortcomings and potential implications with special guests Veronica Miller (Liver Forum) and Hannah Mamuszka (Alva10). This week, SurfingNASHrevisits the topic after a public comments session took place last week. In doing so, patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) explain the why they chose to deliver their specific testimonies.Mike shares a compelling anecdote around the ongoing challenges which persist in the post-recovery of NAFLD. Specifically, he suggests the document made light of bariatric surgery as a treatment option and failed to consider the extent of preparations and persistence which it requires. Wayne expands on his disappointment with the fact that the document does not consider NAFLD/NASH as a progressive disease. As a numbers guy, Tony explains that he chose to discuss the significant fallacies in the populations and numbers chosen for the economic analysis.If you enjoy the episode, have questions or interest around patient advocacy and Fatty Liver disease, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at [email protected] Safe and Surf On!